905 related articles for article (PubMed ID: 30613964)
61. The impact of induction chemotherapy on long-term quality of life in patients with locoregionally advanced nasopharyngeal carcinoma: Outcomes from a randomised phase 3 trial.
Yang Q; Xia L; Lin M; Zhang MX; Duan CY; Liu YP; Xie YL; Wang ZQ; You R; Zou X; Hua YJ; Huang PY; Sun R; Hong MH; Chen MY
Oral Oncol; 2021 Oct; 121():105494. PubMed ID: 34425533
[TBL] [Abstract][Full Text] [Related]
62. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
[TBL] [Abstract][Full Text] [Related]
63. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
64. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.
Wu X; Huang PY; Peng PJ; Lu LX; Han F; Wu SX; Hou X; Zhao HY; Huang Y; Fang WF; Zhao YY; Xue C; Hu ZH; Zhang J; Zhang JW; Ma YX; Liang WH; Zhao C; Zhang L
Ann Oncol; 2013 Aug; 24(8):2131-6. PubMed ID: 23661293
[TBL] [Abstract][Full Text] [Related]
65. Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma.
Wang YW; Ho SY; Lee SW; Chen CC; Litsu S; Huang WT; Yang CC; Lin CH; Chen HY; Lin LC
Int J Med Sci; 2020; 17(5):568-576. PubMed ID: 32210706
[No Abstract] [Full Text] [Related]
66. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
67. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy.
Lv JW; Qi ZY; Zhou GQ; He XJ; Chen YP; Mao YP; Chen L; Tang LL; Li WF; Lin AH; Ma J; Sun Y
Cancer Sci; 2018 Mar; 109(3):751-763. PubMed ID: 29266526
[TBL] [Abstract][Full Text] [Related]
68. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
[TBL] [Abstract][Full Text] [Related]
69. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
70. Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Yuan TZ; Zheng RH
J Cancer; 2021; 12(1):18-27. PubMed ID: 33391399
[No Abstract] [Full Text] [Related]
71. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.
He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X
Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552
[TBL] [Abstract][Full Text] [Related]
72. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.
Chen J; Liu T; Sun Q; Jin T
Medicine (Baltimore); 2020 Jul; 99(29):e20443. PubMed ID: 32702809
[TBL] [Abstract][Full Text] [Related]
73. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
[TBL] [Abstract][Full Text] [Related]
74. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
75. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
[TBL] [Abstract][Full Text] [Related]
76. Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy.
He S; Wu YL; Gao Y; He D; Huang Y
Cancer Med; 2023 May; 12(9):10536-10552. PubMed ID: 37062057
[TBL] [Abstract][Full Text] [Related]
77. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.
Yi J; Huang X; Gao L; Luo J; Zhang S; Wang K; Qu Y; Xiao J; Xu G
Radiat Oncol; 2014 Feb; 9():56. PubMed ID: 24533569
[TBL] [Abstract][Full Text] [Related]
78. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
[TBL] [Abstract][Full Text] [Related]
79. Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma.
Xue F; Ou D; Ou X; Zhou X; Hu C; He X
Oral Oncol; 2022 Nov; 134():106139. PubMed ID: 36179488
[TBL] [Abstract][Full Text] [Related]
80. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis.
Bongiovanni A; Vagheggini A; Fausti V; Mercatali L; Calpona S; Di Menna G; Miserocchi G; Ibrahim T
Crit Rev Oncol Hematol; 2021 Apr; 160():103244. PubMed ID: 33582249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
